
Yale’s picks to beat cancer: a pair of aces
An illustrious new chief of medical oncology, a leader for the Yale Cancer Biology Institute boost efforts to develop better drugs for cancer
It has been an eventful December for the advancement of basic and translational cancer research at Yale. On the 13th, Yale University announced that Joseph Schlessinger, Ph.D., a world-renowned scientist with an unparalleled track record of identifying molecular targets for novel anticancer drugs, was named the first director of the University’s new Cancer Biology Institute (CBI), one of five major interdisciplinary research initiatives located on Yale’s West Campus. Just a week before, Thomas
Alumna supports doctors who join her on a road less traveled

Medicine offers satisfying careers in both science and patient care, and at the School of Medicine, students and...
Built from scratch, lungs are a big leap in bioengineering

Laura Niklason, M.D., Ph.D., has spent the past 15 years in the lab developing ways to build new arteries using tissue...
Medical school’s mentors ‘pay it forward’
Seasoned pros are vital in preparing students to succeed on their own

Tiny scope is a big advance for GI cancers
Last year, when Harry Aslanian, M.D., associate professor of medicine, first looked at images produced by a new...

Annual auction nets more than $25,000 for New Haven charities
The annual student-run Hunger and Homelessness Auction, held on November 18, garnered more than $25,000 for New Haven...
Grants and contracts awarded to Yale School of Medicine
FederalSteven L. Bernstein, NIH, Treating Low-Income Smokers in the Hospital Emergency Department, 5 years,...
Science for its own sake can also hatch payoffs, says a Yale geneticist